2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original Research
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2014
CyTOF supports efficient detection of immune cell subsets from small samples
Yao Y, Liu R, Shin MS, Trentalange M, Allore H, Nassar A, Kang I, Pober JS, Montgomery RR. CyTOF supports efficient detection of immune cell subsets from small samples. Journal Of Immunological Methods 2014, 415: 1-5. PMID: 25450003, PMCID: PMC4269324, DOI: 10.1016/j.jim.2014.10.010.Peer-Reviewed Original ResearchConceptsImmune cell subsetsCell subsetsImmune cell statesPatient biopsiesTranslational investigationsFlow cytometryClinical researchCellular analysisMass cytometryMultiple cell populationsCell populationsCytometryCyTOFSingle-cell analysisMultiparameter single cell analysisFluorescence cytometryFluorescence-based flow cytometryCell statesHuman diseasesMarkersTremendous detailBiopsyPathogenesis
2003
Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease
Biedermann BC, Tsakiris DA, Gregor M, Pober JS, Gratwohl A. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplantation 2003, 32: 1077-1084. PMID: 14625579, DOI: 10.1038/sj.bmt.1704258.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCase-Control StudiesEndothelium, VascularFas Ligand ProteinGraft vs Host DiseaseHematopoietic Stem Cell TransplantationInterferon-gammaLymphocyte ActivationMembrane GlycoproteinsMolecular Diagnostic TechniquesRNA, MessengerSensitivity and SpecificitySurvivorsT-Lymphocytes, CytotoxicTransplantation, HomologousVon Willebrand FactorConceptsCytotoxic T lymphocytesEndothelial injuryT cell activationT cellsT lymphocytesHost diseaseSCT recipientsAllogeneic stem cell transplantationAllospecific cytotoxic T lymphocytesIFN-γ transcript levelsActive chronic GVHDEndothelial injury resultsCD8 T lymphocytesCD8 T cellsCD4 T cellsLong-term survivorsStem cell transplantationImportant effector cellsVon Willebrand factor plasma levelsAge-matched controlsVascular endothelial cellsChronic GVHDActive graftEffector cellsCell transplantation